Case File
efta-efta00993588DOJ Data Set 9OtherDS9 Document EFTA00993588
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00993588
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
To: Jeffrey Epstein <[email protected]>
Subject: Fwd: AOBiome Corporate Update and Investor Call
Date: Thu, 17 Jul 2014 01:08:14 +0000
Have you contacted aobiome?
Interested?
I'm blissed to be at the Media Lab. Freaking bfissed. And love Boston. Perfect place for me!!!
I think it's potentially good for me to have an affiliation with the lab. Need to figure out what, plus other?
affiliations...
I can't wait to move here!!
You really think real estate will drop? Tank? I want to really settle in here.
Xoxo
iPhone feature: Tupos & Abbrvtns
Begin forwarded message:
From: Lenny Barshack
Date: July 16, 2014, 3:42:55 PM EDT
To: Linda
Subject: AOBiome Corporate Update and Investor Call
16-Jul-14
Hello Linda
On Monday 21 July at 3PM EST, I am hosting a conference call to introduce AOBiome to potential investors. I wanted to invite you to
join this call as it will provide a very comprehensive picture of the AOBiomets past, present, and fiiture. While a small part of the
presentation is geared toward investors, the vast majority of the call is generic and something I think you would find interesting.
The eMail that our CFO Joe Grimm is sending out reads...
Hello,
We are delighted to invite you to a presentation highlighting AOBiome's recent and exciting developments and
longer-term investment growth prospects. In addition, we will update existing investors on our recently
initiated Series B fund raising effort where we are seeking to raise $4 million at $1.50 per share from a select
group of new "valued-added" individual investors and existing investors who would like to top-off or
participate to a lesser degree. Initial interest from new investors has been exceptionally strong and we
anticipate closing the round in several weeks.
EFTA00993588
On the call will be our founders, Jamie Heywood, David Whitlock and Lenny Barshack; and our management
team, including Spiros Jamas (CEO), Larry Weiss (Chief Medical Officer), Jasmina Aganovic (Head of
Consumer) and Joe Grimm (CFO). The call is scheduled for this Monday, July 21, 2014 from 3:00 pm to 4:30
pm EST.
Please use the following call-in information:
Monday, July 21, 2014 from 3:00 pm to 4:30 pm EST.
Telephone number
Pass code
The Powerpoint for the presentation, along with other information can be found at: DropBox
AOBiome is The Leading Skin Microbiome Company and we are leveraging our patent portfolio and scientific
knowhow to address growing unmet medical needs in the therapeutic and consumer markets. Therapeutically,
we are developing first in class pharmaceutical products for acne, eczema and diabetic ulcers. These unique
formulations build on our AO+ Mist consumer experience and safety database, promising scientific efficacy
studies in cells and animals, and ten years of microbe strain selection and development. We expect to initiate
clinical studies in 2015 in at least two therapeutic indications.
As Lenny undoubtedly mentioned, our lead consumer product, AO+ Mist, is a proprietary, clinically tested
beneficial microbe (aka "good bacteria") for improving skin appearance and vibrancy. We believe this product
has much potential in several consumer categories and while we have a keen interest in growing the brand and
introducing "biome friendly" soaps and shampoos, you should know we are in discussions with major
consumer health companies, including Unilever, P&G and J&J.
The response to the New York Times Magazine "No Soap No Shampoo" article has been terrific in the number
of emails we've received (>15,000). We have continued to get media coverage from others such as Good
Morning America, NPR and the London Sunday Times. In fact the enthusiasm for AO+ Mist has been far
beyond our expectations largely due to unanticipated high demand from holistically-minded consumers. An
analysis of our emails puts this group slightly ahead of those seeking to improve ongoing skin issues and those
wanting healthier looking skin. This has been confirmed in discussions with consumer products companies —
there is a growing backlash against anti-microbial soaps and the effects of harsh surfactants on the skin
microbiome—and is unlikely to be just a fad. As a result, we believe that the branding and messaging we are
developing will position us to capture a much broader consumer market.
Thank you for your interest and we hope you can join our call,
Joe
Important links when you have time
"No Soap No Shampoo" Article by Julia Scott featured in the New York Times Magazine
Good Morning America, TV segment featuring AO+ Mist and Julia Scott
NPR "On Point" radio broadcast featuring Jamie Heywood and Julia Scott
London Sunday Times featuring our scientific founder, David Whitlock, and AO+ Mist
AOBiome.com
Joseph Grimm
CFO
AOBiome LLC
EFTA00993589
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
aobiome.comEmail
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.